Background: Erdheim-Chester disease (ECD) is a rare form of non-Langerhans cell
ECD, but only 50% of patients describe bone pain. Other hallmark manifestations are periaortic sheathing ("coated aorta"); pericarditis; myocardial infiltration; pulmonary interlobular septal thickening; perinephric infiltrates ("hairy kidneys"); central nervous system involvement; orbital infiltration, resulting in exophthalmos;
endocrinopathies, such as diabetes insipidus; and skin xanthomas and xanthelasmas. It is difficult to diagnose ECD without cutaneous findings in early-stage disease because symptoms are often nonspecific and subjective. Sometimes ECD is only diagnosed at autopsy. [3] [4] [5] [6] Dermatologic findings of ECD include xanthomas of the face, neck, axilla, and trunk, which are found in approximately one-third of people with ECD. 7 Xanthelasmas appear in approximately 25% of patients with ECD. 8 The presence of skin manifestations leads to earlier diagnosis because the lesions are easily identified by dermatologists, and it is easier to obtain a biopsy from the skin than from other organs.
Histopathologic findings of ECD demonstrate infiltration of typically foamy or lipid-laden histiocytes with admixed or surrounding fibrosis. Touton giant cells are often present. The histiocytes in ECD are tissue macrophages devoid of S-100, CD1a, and CD207 surface markers but showing CD68, CD163, and Factor XIIIa immunoreactivity. They also express a pattern of inflammatory cytokines and chemokines, including interferon alpha (IFN-a), 9 interleukin-12 (IL-12), 9 monocyte chemotactic protein-1 (MCP-1), 9,10 interleukin-1 (IL-1), 9 and tumor necrosis factor-alpha (TNF-a). 11 We previously reported that xanthomas proliferated in the region of dermatitis in a patient with ECD. 12 insipidus, and multiple xanthomas of the periorbital, neck, and flexor extremity skin. The other patient (ECD2) was a 44-yearold man with multiple xanthomas of the eyelid, neck, and flexor extremity skin (Figure 1) . No other abnormalities were observed.
Four years later, however, the xanthomas appeared bulkier, and Table 1 ) 17 and KODFX (TOYOBO). The PCR conditions were 94°C for 2 minutes, followed by 36 cycles of amplification (98°C for 30 seconds, 56°C for 30 seconds, 68°C for 30 seconds), and finally 68°C for 3 minutes. After purification of PCR products using LaboPass PCR (Cosmo Gene Tech), the amplified fragment was directly sequenced using BigDye Terminator v3.1.
| Reverse transcription PCR and real-time PCR
Total RNA was isolated using Maxwell 16 LEV simplyRNA Tissue Kit.
RNA concentration was measured with the NanoDrop 2000 spectrophotometer, and RNA integrity was verified on 2% denaturing agarose gels.
ReverTra Ace qPCR RT Master Mix (TOYOBO) was used for RNA reverse transcription. The reaction was conducted in a 10 lL mixture.
Total RNA was reverse-transcribed, and real-time PCR was performed to amplify cDNA via primer sets specific for either BRAF or BRAF pseudogenes-speS, speAS, pS1, pS2, and pAS ( Figure 3 , Table 1 ) 17 was amplified in both patients. The BRAFV600E mutation was detected in ECD1, but not in ECD2, during sequence analysis (Figure 4 ).
| ECD1 and ECD2 exhibited overexpression of

BRAF and BRAF pseudogenes compared with normal tissues
No genomic contamination was evident, as no amplification was observed when using mRNA as a template. Figure 5 ). The PCR products using BP-0 primers were 449 base pairs (bp) and using BP-1 primers were 334 bp, including the intron.
Thus, there was no splicing out of the BRAF pseudogene, as previously reported, 16, 17 and no mutation in the PCR products based on sequencing analyses. Expression levels of both BRAF and BRAF pseudogenes were higher in xanthomas than in normal tissues ( Figure 5 ).
| DISCUSSION
The macrophages in our ECD cases showed positivity of CD163, which shows M2-like polarized tumor-associated macrophages promoting cancer cell growth. 18 Recent studies demonstrate that many patients with ECD have mutations in BRAF, NRAS, and other genes involved in the MAPK activation pathway (similar to lymphoma), leading to categorization of ECD as a lymphoid neoplasm. It is also possible that in the absence of the BRAFV600E mutation, those patients showing elevated BRAF expression may benefit from this treatment as well.
Herein, we profiled 2 patients with ECD, both showing heightened expression of BRAF gene and BRAF pseudogenes, with or without the BRAFV600E mutation. Aside from BRAF mutation status, expression levels of BRAF and BRAF pseudogenes will likely help identify patients with ECD who are candidates for vemurafenib. We examined NRAS-61 mRNA levels in xanthomas from both patients but found no mutations. It is unclear whether mutations in other genes play a role in these cases. The etiologic ramifications of BRAF or BRAF pseudogenes in patients with ECD will be the focus of future study.
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